Canada: Recall: Lynparza® Capsule 50mg (English Only)
 
Health Canada announces that AstraZeneca Canada Inc. is recalling 3 lots of Lynparza® (olaparib) Capsule 50mg (lot number: NG944, NG695, NK349) from wholesaler/pharmacy because during on-going stability monitoring, an out of specification was found with the affected lots. 

Please refer to the following website in Health Canada for details: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../66108r-eng.php 

In Hong Kong, Lynparza Capsules 50mg (HK-64538) is a pharmaceutical product registered by AstraZeneca Hong Kong Ltd (AstraZeneca), and is a prescription-only medicine. As confirmed with AstraZeneca, the affected batches in Canada have not been imported into Hong Kong. On 21 Feb 2018, the Department of Health (DH) endorsed AstraZeneca to recall 3 other batches (batch number: NG699, NF848, NJ141) of the product in Hong Kong which were affected by the same issue. The DH has been closely monitoring the recall. 

Ends/Wednesday, Mar 7, 2018 
Issued at HKT 16:00 

 轉載自衛生署藥物辦公室網頁http://www.drugoffice.gov.hk/ 
Related Information:
The United Kingdom: Class 3 Medicines Recall: Lynparza capsule 50mg (olaparib) (... 上載於 2018-03-13
回收三個批次的Lynparza Capsules 50mg產品 上載於 2018-02-21